Pharma Focus Asia

Pharma Press Releases

Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

Novo Integrated Sciences’ Subsidiary, Clinical Consultants International, Signs Consulting Agreement with Pharmaceutical Research & Development Company, Sarfez Pharmaceuticals, Inc.

Wednesday, November 30, 2022

Novo Integrated Sciences Inc and Clinical Consultants International LLC CCI a Novo whollyowned subsidiary today announced the signing of a Consulting Agreement the Agreement with Sarfez Pharmaceuticals Inc Sarfez a pharmaceutical research and develop...

IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies

Wednesday, November 30, 2022

IPA an advanced biotherapeutic research and technology company today announced that BioStrand BV an AI in silico discovery subsidiary of IPA has entered into a research collaboration and license agreement the Agreement with BriaCell Therapeutics Corp...

Immutep enters into second clinical trial collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer for new combination study of its first-in-class LAG-3 candidate

Tuesday, November 29, 2022

Immutep Limited a clinicalstage biotechnology company developing novel LAG immunotherapies for cancer and autoimmune disease is pleased to announce it has signed a Clinical Trial Collaboration and Supply Agreement Agreement with Merck KGaA Darmstadt...

SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences

Tuesday, November 29, 2022

SOTIO Biotech a clinical stage immunooncology company owned by PPF Group today announced that is has exercised its first of five exclusive targetspecific options with LegoChem Biosciences LCB KOSDAQ for antibodydrug conjugate ADC SOT which is curren...

Cipla announces launch of leuprolide acetate injection depot (22.5mg)

Tuesday, November 29, 2022

Cipla Limited and its wholly owned subsidiary Cipla USA Inc today announced the launch of Leuprolide Acetate Injection Depot mg The product was approved by the United States Food and Drug Administration US FDA based on a New Drug Application NDA subm...

Eikonoklastes Therapeutics and Forge Biologics Announce Viral Vector Contract Development and AAV Manufacturing Partnership

Tuesday, November 29, 2022

Eikonoklastes Therapeutics a preclinical biotech company developing treatments for todays most challenging diseases and Forge Biologics a gene therapyfocused contract development and manufacturing organization today announced a manufacturing partners...

AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy

Tuesday, November 29, 2022

Neogene Therapeutics Inc a global clinicalstage biotechnology company pioneering the discovery development and manufacturing of nextgeneration Tcell receptor therapies TCRTs today announced it has entered into a definitive agreement to be acquired by...

Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa

Tuesday, November 29, 2022

Bioventure a Dubaibased pharmaceutical company Minapharm Pharmaceuticals a Cairobased pharmaceutical company and MiGenTra GmbH a Berlinbased pharmaceutical company announced today the signing of an exclusive license agreement for the commercializatio...

Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy

Monday, November 28, 2022

Tenaya Therapeutics a clinicalstage biotechnology company with a mission to discover develop and deliver potentially curative therapies that address the underlying causes of heart disease today announced that the US Food and Drug Administration FDA h...

Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies

Monday, November 28, 2022

Enlivex Therapeutics Ltd a clinicalstage macrophage reprogramming immunotherapy company today announced that the US Food Drug Administration FDA has cleared an Investigational New Drug IND application to study Allocetra in patients with advanced sol...